Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Current Leases (2019 - 2025)

Historic Current Leases for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $2.2 million.

  • Protagonist Therapeutics' Current Leases rose 485111.11% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 485111.11%. This contributed to the annual value of $510000.0 for FY2024, which is 5530.24% down from last year.
  • According to the latest figures from Q3 2025, Protagonist Therapeutics' Current Leases is $2.2 million, which was up 485111.11% from $2.2 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Current Leases high stood at $2.6 million for Q1 2023, and its period low was $45000.0 during Q3 2024.
  • Its 5-year average for Current Leases is $1.8 million, with a median of $2.1 million in 2021.
  • In the last 5 years, Protagonist Therapeutics' Current Leases tumbled by 9750.42% in 2024 and then skyrocketed by 485111.11% in 2025.
  • Quarter analysis of 5 years shows Protagonist Therapeutics' Current Leases stood at $2.2 million in 2021, then grew by 14.32% to $2.5 million in 2022, then crashed by 54.63% to $1.1 million in 2023, then plummeted by 55.3% to $510000.0 in 2024, then skyrocketed by 336.86% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $2.2 million for Q2 2025, and $1.6 million during Q1 2025.